Dr Jason Brown
Jason co-founded Ubiquigent in 2009 in collaboration with the University of Dundee, the Medical Research Council and a US biotech. Ubiquigent’s mission is to support and enable client ubiquitin system targeted drug discovery through the identification and characterisation of novel compounds across multiple therapeutic areas. The company is a provider of such collaborations and services worldwide to both commercial pharmaceutical and biotechnology companies as well as academic groups. Before starting Ubiquigent he was part of a biotech investment and operations group and involved in supporting molecular diagnostics, kinase drug discovery and various other drug discovery-focused service companies, along with evaluating investment opportunities. Prior to this he built and ran a kinase-focused assay development and drug discovery service facility for Upstate Biotechnology, a leading provider of cell signalling research products and services. Jason received his MPhil and DPhil from the University of Cambridge in association with Parke-Davis/Warner-Lambert (Pfizer), during which he identified a voltage-dependent calcium channel subunit as the novel molecular target of the blockbuster epilepsy and neuropathic pain drugs Neurontin and Lyrica. After his DPhil Jason worked in and subsequently ran an assay development group for Parke-Davis.
